Publicaciones en colaboración con investigadores/as de Tongji University (5)

2024

  1. Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 121, Núm. 36

2022

  1. Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer

    Clinical Cancer Research, Vol. 28, Núm. 8, pp. 1640-1650

2020

  1. Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma

    JCI Insight, Vol. 5, Núm. 15

  2. Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 117, Núm. 39, pp. 24415-24426

2018

  1. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS

    Cell, Vol. 172, Núm. 4, pp. 857-868.e15